Evidence-Based Formulation of Antibiotics Classification Management Lists in Beijing Medical Institutions
XU Xiao-han1a,2,3, ZHOU Peng-xiang1a,2,3, KONG Xu-dong4, CAO Zhao-long5, CHENG Yin-chu1a,2,3, GU Li6, Haishaerjiang·Wushouer7, 8, HE Bei1b, HU Xin3,9, LIU Chao-hui10, LIU Qing-hua11, MA Xiao-jun12a, MA Xu-zhu13, QI Wen-jie14a, SU Jian-rong14b, WANG Rui15, WANG Xiao-ling16, XU Ying-chun12b, YAN Ying-ying1a,2,3, YANG Yang11, YING Ying-qiu1a,3, ZHAI Suo-di1a,2,3, ZHAO Zhi-gang3,17, ZHEN Jian-cun3,18, ZHOU Ying19a, ZHU Guang-fa20, ZHENG Bo3,19b*, YANG Yi-heng1a,2,3*
1. a. Department of Pharmacy, b. Department of Pulmonary and Critical Care Medicine, Peking University Third Hospital, Beijing 100191, China; 2. Beijing Pharmacy Center for Quality Control and Improvement, Beijing 100191, China; 3. Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China; 4. Department of Pharmacy, China-Japan Friendship Hospital, Beijing 100029, China; 5. Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing 100044, China; 6. Department of Infection Diseases and Clinical Microbiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China; 7. School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; 8. International Research Center for Medicinal Administration, Peking University, Beijing 100191, China; 9. Department of Pharmacy, Beijing Hospital, Beijing 100730, China; 10. Department of Gynecology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing 100026, China; 11. Department of Pharmacy and Medical Equipment, Beijing Municipal Health Commission, Beijing 100053, China; 12. a. Department of Infectious Medicine, b. Department of Clinical Laboratory, Peking Union Medical College Hospital, Beijing 100730, China; 13. Department of Infectious Disease, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing 102218, China; 14. a. Department of Infectious Medicine, b. Clinical Laboratory Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China; 15. Room of Medicine Clinical Research, Department of Pharmacy, Centre of Medical Security, Chinese People's Liberation Army General Hospital, Beijing 100853, China; 16. Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China; 17. Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China; 18. Department of Pharmacy, Beijing Jishuitan Hospital, Beijing 100035, China; 19. a. Department of Pharmacy, b. Institute of Clinical Pharmacology, Peking University First Hospital, Beijing 100034, China; 20. Department of Respiratory and Critical Care Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China
Abstract：OBJECTIVE To explore the establishment of drug list selection method based on evidence-based medicine, and to revise the Antibiotics Classification Management Lists in Beijing Medical Institutions, so as to provide supports for the scientific formation of drug lists and the rational application of antibiotics. METHODS The Beijing Municipal Health Commission established a multidisciplinary drug list working group to integrate drug data, drug evidence and expert opinions based on the plan of drug list, and to form expert consensus on the classification management list through the Delphi method according to the inclusion and exclusion criteria. RESULTS A total of 99 kinds of drugs were included in the selected classification management list. Compared with the previous classification management list, 10 kinds of antibacterial drugs were added, and 38 kinds of antibacterial drugs were called out. Except that 5 kinds of antibacterial drugs were raised in management level, 13 kinds of antibacterial drugs were downgraded in management level. CONCLUSION Guided by the thought and methods of evidence-based medicine, through comprehensive evidence and data support, combined with the experience of multidisciplinary experts, and scientific consensus methods, the scientificity and rationality of the revision of the drug list can be improved.
Ministry of Health of the People's Republic of China. Notice on the implementation of the “Guidelines for Clinical Use of Antibacterials” [EB/OL]. (2004-08-19) [2022-06-06]. https://www.nmpa.gov.cn/xxgk/fgwj/qita/20040819010101741.html.
[2]
ZHANG Z F. Monitoring of the multiple resistant bacteria and development of new antibiotics[J]. Chin Pharm J (中国药学杂志), 2014, 49(14):1268-1273.
[3]
Ministry of Health of the People's Republic of China. The management measures for the administration of clinical use of antibacterials [EB/OL]. (2012-04-24) [2022-06-06]. http://www.gov.cn/flfg/2012-05/08/content_2132174.htm.
[4]
BEIJING MUNICIPAL BUREAU. Notice on printing and distributing antibiotics classification management lists in medical institutions of Beijing (for trial implementation) [EB/OL]. (2012-08-02) [2022-06-06]. http://wjw.beijing.gov.cn/zwgk_20040/fgwj/wjwfw/201912/t20191219_1303145.html.
[5]
LIANG X L, TAN L, TAN L, et al. Utilization analysis of antibiotics in Beijing Hospital during 2012-2015[J]. Clin Med J (临床药物治疗杂志), 2016, 14 (4):55-60.
[6]
FANG P Q, MIN R, YIN X X, et al. Problems and countermeasures on the management and application of antiseptic drugs in Chinese hospitals[J]. Chin J Hosp Adm (中华医院管理杂志), 2018, 34 (8), 655-658.
[7]
ZHANG X, YANG Y Y, ZHOU Y, et al. Analysis of provincial antibiotic classification management lLists in China[J]. J China Pharm (中国药房), 2021, 32 (16):1921-1925.
[8]
THE GENERAL OFFICE OF THE NATIONAL HEALTH COMMISSION. Notice of the general office of the national health commission on continuing to manage the clinical application of antibacterial drugs. (2020) [EB/OL]. (2020-07-23) [2022-06-06]. http://www.nhc.gov.cn/yzygj/s3593/202007/8311bda4cf2443dfae4d719f1d0d72da.shtml.
[9]
National Health Commission of the People's Republic of China, National Administration of Traditional Chinese Medicine. Notice on printing and distributing national essential drug list(2018) [EB/OL]. (2018-10-30) [2022-06-06]. http://www.gov.cn/fuwu/2018-10/30/content_5335721.htm.
[10]
Chinese National Formulary Committee. Chinese National Formulary Chemicals and biological products. 2nd ed(中国国家处集化学药品与生物制品卷第2版) [M]. Science Press, 2020.
[11]
NATIONAL HEALTHCARE SECURITY ADMINISTRATION. Notice on printing and distributing national basic medical insurance, industrial injury insurance and maternity insurance (2020) [EB/OL]. (2020-12-28) [2022-06-06]. http://www.nhsa.gov.cn/art/2020/12/28/art_37_4220.html.
[12]
WORLD HEALTH ORGANIZATION. WHO access, watch, reserve (AWaRe) classification of antibiotics for evaluation and monitoring of use, 2021[EB/OL]. (2021-04) [2022-06-06]. https://apps.who.int/iris/handle/10665/345555.
[13]
ZHOU Q, WANG Q, YU Y, et al. Consensus methods in the development of clinical practice guidelines [J]. Drug Eval(药品评价), 2016, 13(16):13-17.
[14]
BEIJING MUNICIPAL HEALTH COMMISSION. Notice on printing and distributing antibiotics classification management lists in Beijing medical institutions (2021) [EB/OL]. (2021-05-18) [2022-06-06]. http://wjw.beijing.gov.cn/zwgk_20040/qt/202105/t20210518_2392236.html.
2023, Vol. 58 
